Multiple sclerosis trials recruiting in Arizona

All Multiple sclerosis trials nationally

Cities in Arizona

Recruiting trials in Arizona

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Gilbert, Phoenix, Scottsdale
• A Study of AZD0120 in Autoimmune Diseases
  NCT07295847 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Tucson
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
  NCT07067463 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Arizona: Pheonix, Scottsdale
• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
  NCT07299019 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Arizona: Phoenix, Scottsdale
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Arizona: Phoenix, Tucson
• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
  NCT06782490 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Arizona: Scottsdale
• AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
  NCT06063850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Phoenix
• An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
  NCT07224373 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Arizona: Tucson
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · Arizona: Scottsdale
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Arizona: Phoenix, Scottsdale
• PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
  NCT07142291 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Scottsdale
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Arizona: Tucson
• Study of COYA 302 for the Treatment of ALS
  NCT07161999 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Arizona: Phoenix